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ABSTRACT 
We examined the effects of arachidonic acid metabolites on the simultaneous 
expression of procoagulant (PC) and plasminogen activator (PA) activities by rabbit 
alveolar macrophages. Incubation with lymphocyte-conditioned medium (LCM) 
caused a significant increase in cell-associated PC activity. Co-treatment with 
indomethacin (1 @I) reduced this augmentation in PC activity by 33% (p < 0.05). In 
contrast, indomethacin caused a 42% increase in PA activity released into incubation 
medium (p < .OS). Both effects of indomethacin were reversed by the addition of 
PGE2 in concentrations as low as 1 nM. Addition of 100 nM PGE2 to these cells 
caused an increase in PC activity 2.7-fold greater than that achieved by LCM alone, 
while PGE2 suppressed released PA activity by 62%. PGE2 and indomethacin had 
similar but less pronounced effects on phorbol myristate acetate-treated cells. These 
effects of PGE2 could be duplicated by PGEr, but not by any other arachidonic acid 
metabolite (PGFza, PGI2, PGD2, ddPGFzcc, LTB4, or LTC4). While PGE2 
increases intracellular levels of CAMP, the observed effects on PC and PA activities 
could not be reproduced fully by treatment with dibutyryl CAMP. We conclude that 
PGE2 amplifies the augmentation of PC activity by stimulated alveolar macrophages 
while concurrently inhibiting expression of plasminogen activator. This suggests that 
PGE2 may be a significant mediator in regulating the highly interactive processes of 
inflammation and coagulation/fibrinolysis. 
INTRODUCTION 
Arachidonic acid metabolites are increasingly recognized as important in regulating expression of 
inflammatory responses (1-16). We previously demonstrated that prostaglandin (PG)E;! is 
necessary for the augmented expression of procoagulant (PC) activity by rabbit alveolar 
macrophages stimulated by bacterial lipopolysaccharide. This observation led us to hypothesize 
that PGE;! may represent an important regulatory link between inflammatory and coagulation 
pathways (17). However, macrophages also promote fibrinolysis, chiefly by elaborating a 
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plasminogen activator (PA) (l&19). Thus, the net effect of macrophages on fibrin turnover during 
inflammation must be viewed in the context of the simultaneous expression of competing 
procoagulant and fibrinolytic activities. Because there is limited evidence that PGE2 suppresses 
plasminogen activator activity of elicited macrophages (20,21), we undertook to expand our earlier 
study by examining the role of cyclooxygenase and lipoxygenase metabolites on the concomitant 
expression by macrophages of both procoagulant and plasminogen activator activities. 
METHODS 
Animals - Male New Zealand white rabbits (1.5 to 2 kg) were given routine care in the Unit for 
Laboratory Animal Medicine, University of Michigan Medical Center. 
Bm - Rabbits were sacrificed by intravenous injection of sodium pentobarbital 
and exsanguinated prior to lavage. The trachea was cannulated and the lungs lavaged with 35 ml 
aliquots of Dulbecco’s talcum-magnesium-free phosphate buffered saline (PBS; Gibco, Grand 
Island, NY) at 37’C until 300 ml of lavage fluid was returned. Cell pellets were treated with 110 
mM ammonium chloride in 100 r&i Tris buffer (pH 7.0) to lyse contaminating erythrocytes. The 
cells were then washed three times in serum-free culture medium consisting of RPMl-1640 
(Gibco) containing penicillin (100 U/ml), streptomycin (100 pg/ml), gentamicin (100 pg/ml), 
polymixin B (100 U/ml), and lactalbumin hydrolysate (0.2%, Gibco). In all cases, cell viability 
was greater than 95% by trypan blue exclusion. Cell preparations were consistently more than 
95% alveolar macrophages (22). 
Prenaration of Additives. Lymphocyte-conditioned medium (LCM) was used as a crude source of 
lymphokines. Lymphocyte suspensions were prepared from normal rabbits as described 
previously (19). Cell suspensions were prepared in standard culture medium from the non- 
adherent cells of minced paraortic lymph nodes (> 95% lymphocytes) and incubated in 75 ml 
culture flasks (Falcon Labware, Oxnard, CA) for 48 hours at 5 x lo6 cells/ml in medium 
containing Concanavalin A bound to Sepharose 4B beads (5 pg/ml Con A; Pharmacia Chemicals, 
Piscataway, NJ). After incubation, the LCM was freed of cells and Con A-Sepharose by 
cenhifugation, sterilized by filtration, and stored at -7O’C. Preliminary experiments indicated that a 
1:8 dilution of LCM was optimal, and one such preparation was used in all subsequent 
experiments. Prostaglandins (PG) and leukotrienes (LT) were generous gifts of the Upjohn 
Corporation, Kalamazoo, MI. All were stored at -20°C in ethyl alcohol. Indomethacin (Sigma) 
was freshly dissolved in ethyl alcohol (10 mg/ml). All additives were further diluted in culture 
medium such that the final concentration of ethyl alcohol in cell cultures did not exceed 0.01%. 
The semiselective lipoxygenase inhibitors nordihydroguiaretic acid (NDGA; Aldrich Chemicals, 
Milwaukee, WI) and nafazatrom (Burroughs Wellcome, Research Triangle, NC) were dissolved 
directly in culture medium. Phorbol myristate acetate (PMA; Consolidated Midland, Brewster, 
NY) was stored at -20°C dissolved (1 mg/ml) in dimethylsulfoxide (DMSO) and freshly diluted in 
culture medium for each experiment so that the final DMSO concentration did not exceed 10 parts 
per million. 
Cell Culture. One million cells were dispensed in 1 ml of the serum-free culture medium and 
incubated in duplicate in sterile 12 x 75 mm polypropylene tubes for 24 hours at 37’C in 5% CO2- 
enriched air. Cells were exposed to the various additives for the entire incubation period, as 
indicated. Following incubation, the cells were collected by centrifugation and resuspended in 1 
ml of fresh medium. Both cell suspensions and conditioned incubation media were stored at -20°C 
prior to assay. 
sonication. 
Cell lysates were prepared for assay by two cycles of freeze-thawing followed by 
. . Procoagulant Acav ltv Assay. Procoagulant activity was measured using a one-stage coagulation 
assay (22). Briefly, 100 ~1 volumes of test material, 25 mM CaC12, and titrated normal rabbit 
plasma were mixed sequentially at 37’C and the time required for fibrin formation was measured 
with a coagulation timer (BBL Fibrosystem, Cockeysville, MD). Coagulation times of each 
sample were measured twice and averaged (measurements consistently agreed within lo-15%). 
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The means of the duplicate samples were then translated into arbitrary units of PC activity using a 
standard curve based on the linear relationship between the log concentration of procoagulant 
material and the log of the msultant coagulation time (22). Preliminary experiments confirmed our 
prior observations that only a smal1 fraction of the PC activity generated by these cells was released 
into the culture medium, and that the released activity varied in parallel with cell-associated activity 
(22). Accordingly, we routinely assayed PC activity only in cel1 lysates. None of the 
pharmacologic agents used in the study affected the assay for PC activity. 
Plasminouen Activator Assav, PA activities of incubation media and cel1 lysates were measured 
with a modified 1~1~fibrin plate assay, as described previously in detail (18,19). In brief, 60 pg 
of human fibrinogen (Kabi, Stockholm, Sweden) containing 2 x 105 cpm of 1251-labeled 
fibrinogen (Amersham, Arlington Hts, IL) was dried onto 16 mm plastic culture wells and 
converted to fibrin with 5% fetal bovine serum (Gibco). Human plasminogen was purified by 
lysine-Sepharose affmity chromatography (23) and added in an optimal concentration (2 to 6 pg 
protein/ml) along with test samples to the fibrin wells. lzI activity released into the incubation 
medium was measured after 4 hours at 37OC. The cpm xeleased only in the presence of test sample 
and plasminogen was taken to represent PA activity. Net lui release was calculated as the percent 
of maximal release achieved by trypsinizing the wells; percent lysis was then translated into milli- 
Plough units @PU) using a standard curve generated with human urokinase (Sigma Chemicals, 
St. Louis, MO). 1251 release was negligible in the absente of added plasminogen; therefore, 
plasminogen-independent fibrinolysis was not examined further. None of the pharmacologic 
interventions affected the t*sI-fibrin assay. It is important to emphasize that this assay only 
measures plasminogen-dependent fibrinolysis, and the results may reflect changes in either 
plasminogen activator proteins or plasminogen activator inhibitors. Therefore, PA is only 
discussed in terms of activity, and not concentrations of specific proteins. 
Cvclic Adenosine Mononhosnhate (cAM.P) Assav, Intracellular cAMP levels were measured with 
a double antibody radioimmunoassay (24). The limit of sensitivity was 10 fmole/ml, and inter- 
and intra-assay variabilities were 2.7% and 2.9%, respectively. This assay only cross-reacted with 
ó-fold greater concentrations of adenosine monophosphate and at least 400-fold greater 
concentrations of other purine nucleosides and nucleotides. Assays were performed by the 
laboratories of the Diabetes Training and Research Center, University of Michigan Medical Center. 
Multiple comparisons to control groups were perfomud using Dunnett’s test applied to Statistics. 
a one-way analysis of variante. Single comparisons were tested with the unpaired Student’s t test 
(25). 
RESULTS 
Pr acron ocoauu an and nlasminouen activator activities of normal a d st 1 t imul ated h=In 
keeping with our previous studies (19,22), fìeshly isolated alveoyar macrophagi expressed both 
procoagulant and plasminogen activator activities (Table 1). Cell lysates accelerated coagulation of 
normal plasma to 197 f 3 1.6 s, compared to spontaneous coagulation times of recalcified plasma 
consistently greater than 500 sec. When cells were incubated for 24 hours in standard culture 
medium, there was a modest but significant increase in PC activity (105 f 7.7 sec; p c 0.001). 
The addition of LCM to the culture medium caused a further increase in PC activity (88.5 t 6.7 
sec; p < 0.05). Maximal stimulation with PMA (10 nM) caused a marked incmase in procoagulant 
activity (47.1 f 3.6 sec; p < 0.001). Prior studies have shown that this procoagulant activity 
functions as a tissue thromboplastin, activating the extrinsic coagulation pathway (22). 
Lysates of freshly isolated macrophages expres& low levels of plasminogen activator activity 
(93.8 f 25 mPU/106 cells). When cells were cultured for 24 hours, the lysate activity increased to 
358 i: 84 mPU/106 cells (p < 0.001). In addition, 642 f 155 mPU/ml was present in the culture 
medium. LCM did not affect expression of PA in either lysates or incubation media (p > 0.5), but 
PMA caused marked incteases in both activities (Table 1). We have shown that this plasminogen 
activator has immunologie and molecular weight characteristics of a urokinase rather than a tissue 
plasminogen activator (26). Preliminary experiments (not shown) verified that the effects of LCM 
524 PROCOAGULANT AND PA Vol. 51, No. 5 
and PMA on PC and PA activities were not affected by the presence or absente of polymyxin B, 
indicating that the effects were not due to contaminating endotoxin (17). 
TABLE 1: Procoagulant and Plasminogen Activator Activities of Normal 
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Effects of indo- 
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: 
expression of PC and PA act- 
’ 
ivities by rabbit alveolar macro- 
phages stimulated with lympho- 
n g cyte conditioned medium. Data 
i 
are expressed as the % of control 
values from cells cultured with 
LCM alone. Mean f SEM, N=6, 
100 j except for 1OOnM PGE2, where 
2 N=12. A single asterisk denotes 
0 p < 0.01. Two asterisks denote p 
u c 0.05. m: PC activity. The 
increase in PC activities above 
levels of freshly-harvested cells is 
displayed on the ordinate at the 
left. Corresponding coagulation 
times are shown at the right (log 
scale). Indomethacin suppressed 
the increase in PC activity by 
33%. As little as 1 nM PGE2 re- 
versed this effect and an optimal 
dose stimulated an increase in PC 
activity 2.7 fold greater than 
conttol values. v: PA act- 
ivity. Indomethacin increased 
release of PA activity to 142% of 
control values, and the addition of 
PGE2 suppressed PA activities in 
cel1 lysates and incubation media 
to as little as 33% and 20% of 
controls, respectively. 
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Effects o cvc ooxvgenase nroducts on . . . C mvmes of LCM-tr& cells, Co-treatment 
with indofmetl!acin (1l.M) blunted the I!CM-stimulated increase in PC activity by 33% (pcO.O5* 
Figure 1A) This cotresponded to prolongation in coagulation times to 100.1 f 6.1 seconds (p ; 
0.1). The inhibitory effects of indomethacin were completely reversed by the addition of PGE2 in 
concenuations as low as 1 nM. Higher concentrations of PGE2 further augmented the resultant PC 
activity, with 100 nM concentrations stimulating almost 3-fold greater PC activity compared to 
cells treated with LCM alone (Figure 1A). This represented a decrease in coagulation times to 72.6 
f 3.6 seconds (pcO.001). Neither indomethacin nor PGE2 alone altered PC activity unless a 
conditioning stimulus such as LCM was present, confirming our prior observations (17). 
The PA activities in lysates and incubation media from control cells were variable, but 
indomethacin caused consistent and significant increases in PA activity released into incubation 
media, reaching 142% of control vahres (pc 0.05; Figure 1B). Addition of PGE2 in doses as low 
as 1 nM reversed the effect of indomethacin, while higher concentrations caused further 
suppression of PA activity. The effect was dose-related, with 100 nM PGE2 maximally 
suppressing both cell-associated and released PA activities to 33% and 38% of controls, 
respectively (p< 0.01). In time course studies, the effects of PGE2 on PC and PA activities both 
appeamd after incubation for 8 hours. Unlike the augmentation of PC activity, the suppression of 
PA activity by PGE2 did not require co-treatment with a conditioning stimulus such as LCM, as 
identical suppressive effects were seen when PGE2 was added alone to normal rabbit alveolar 
macrophages (not shown). 
To determine if augmentation of PC and suppression of PA activities were specific to PGE2, 
macrophages were incubated with LCM, indomethacin (1 PM), and PGE2, PGEl, PGF2a, PGI2, 
PAOSTAGLANDIN t 100 nM1 
(PLUS LCM AN0 IN001 
Figure 2, The effects of various 
prostaglandins (100 nM) on PC 
and PA activities released by 
rabbit alveolar macrophages 
stimulated with lymphocyte- 
conditioned medium.. Ac tivities 
are expressed as % of contml val- 
ues of cells cultured in parallel 
with LCM alone. Mean f SEM, 
N=5. Data are expres& as in 
Figure 1. m: Of the 5 prosta- 
glandins examined, only PGEp 
stimulated an increase in PC 
activity, reversing the effects of 
indomethacin. 
BOTTOM: Both PG& and PGEt 
markedly suppmssed PA activities 
of cell lysates and incubation 
media, but the other prosta- 
glandins had no effect. 
0 PROSTAGLANOIN (100 nMl 
(PLUS LCM AN0 IN001 
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PGD2, and the synthetic thromboxane mimic ddPGF2a. In al1 cases, concenuations ranging from 
1 to 10,000 nM were evaluated, and representative results (100 nM) are shown in Figure 2. Gnly 
PGE2 could reverse the effect of indomethacin on PC activity (Figure 2A), while both PGE2 and 
PGEr suppressed expression of PA activity (Figure 2B), indicating these effects are specific to 
prostaglandins of the E series. 
During these studies, we noted that LCM caused a slight but relatively consistent decrease in PA 
activity. In a prior study, another lot of LCM prepared in identical fashion caused modest 
increases in PA activity (19). In light of the potent suppressive effects of even 1nM PGE2, we 
sought to determine if the variability between lots of LCM could be explained by presence of trace 
amounts of PGE2. Indeed, the LCM preparation used in this study contained 0.1 nM 
immunoreactive PGE2 by radioimmunoassay, raising the possibility that trace contamination with 
PG& could have intluenced the effect of LCM on macrophage PA activity. 
Effects of PGE, on PMA-stimulated macroDhag!$& We sought to determine if PGE2 had similar 
modulating effects on macrophages maximally stimulated by PMA, which unlike LCM stimulates 
marked increases in both PC and PA activities. The addition of indomethacin (1 p.M) consistently 
and significantly (p < 0.05) reduced the PC activity of PMA-stimulated macrophages, although the 
remaining activity was stil1 much higher than unstimulated cells @gure 3A). PGE2 and PGEr 
completely reversed the suppressive effects of indomethacin, while PGF@ had no effect. 
Indmthacin caused a 38% increase in PA activity mleased by PMA-stimulated cells (p < 0.05) 
*o ( .- 
Fieure 3 The effects of 
indomethacin and PG’s (100 nM) 
on PC and PA activities of rabbit 
alveolar macrophages maximally 
stimulated with PMA (10 nM). 
Data are expressed as % of 
control values from cells incub- 
ated with PMA alone. Mean f 
SEM, N=4. Differences bet- 
ween bracketed groups for which 
p c .05 are denoted by an aste- 
risk. Tpp: PC activity. The in- 
crease in PC activity above that of 
freshly harvested cells is 
displayed on the ordinate at the 
left. Corresponding coagulation 
times are shown on the ordinate at 
the right (log scale). Indometh- 
acin suppressed the augmentation 
of PC activity of PMA-treated 
cells by 20%. Addition of either 
PGE2 or PGEr completely 
reversed this effect. In contrast, 
PGF2a had no effect on PC 
activity.. BO’ITOM: PA activity. 
Indomethacin stimulated a 38% 
increase in PA activity released 
into incubation media. This effect 
was also reversed by PGEp and 
PGEr, but not PGF2cx. 
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Again, this effect was reversed by PGE2 and PGEt, but not PGF2a (Figure 3B). Although the 
changes induced by indomethacin and PGE were smaller in pmportion to the high levels of these 
activities stimulated by PMA, these results are qualitatively similar to those of LCM-treated cells. 
To determine if pnxlucts of the lipoxygenase pathway can also alter macrophage PC and PA 
activities, cells were tmated with the semiselective lipoxygenase inhibitors NDGA (1@4) or 
nafazatrom (1 @vi). When used in doses that should not signitkantly inhibit cyclooxygenase 
activity (27), neither agent had any consistent effect on either PC or PA activity of normal or LCM- 
treated cells (not shown). Further, addition of LTB4 and LTC4 (0. l- 10 nM) had no significant 
effect on either activity in normal macrophages or in cells submaximally stimulated witb PMA (2 
nM) (not shown). Taken together, these results suggest that leukotrienes have considerably less 
effects, if any, on these macrophage functions compared to prostaglandin E2. 
Role of cAMP in PGET-Mediated Effects on PC and PA Activities, To determine if PGE 
modulates macrophage PC and PA activities by altering adenylate cyclase activity (28,29), we fust 
examined the effect of PGE2 on intracellular levels of cAMP. The addition of PGE2 (100 pM) to 
normal macrophages cultured for 60 minutes increased intracellular levels of cAMP by 77 zk 30%, 
compared to control values (p < 0.05). Experiments were then performed to determine if 
exogenous cAMP could mimic the effects of PGE2 on PC and PA activities. Dibutyryl cAMP (db- 
cAMP;lpM to 1mM) was added to standard macrophage cultures for 24 hours. As shown in 
Figure 4, an optimal concentration of db-cAMP (1mM) acted like PGE2 in decreasing release of 
PA activity by both normal macrophages (42% control; p < 0.05) and cells submaximally 
stimulated by 2 nM PMA (57% control; p < 0.01). Lysate PA activities were similarly decreased 
by 57% and 59% (p < O.Ol), respectively (not shown). However, db-cAMP had no consistent 
effect on PC expression by normal or PMA-stimulated macrophages. 
200 
















Fieure 4. The effect of 
dibutyryl cyclic-AMP (1 mM) 
on procoagulant activities of 
cel1 lysates and plasminogen 
activator activities released 
into media by rabbit alveolar 
macrophages. Mean f SEM, 
N=6. Data are expres& as % 
of their respective control 
values of cells incubated in 
either medium alone or in the 
presence of PMA (2 nM). 
Dibutyryl-cAMP suppressed 
released PA activities of un- 
stimulated and PMA stim- 
ulated macrophages by 48% 
and 52%, respectively (p < 
0.05). db-cAMP had no con- 
sistent effect on PC activity in 
either group. 
Interactions between mononuclear phagocytes and the coagulation and fibrinolytic pathways appear 
to have a role in the pathogenesis of delayed-type hypersensitivity and other inflammatory 
conditions (30,31). Expression by mactophages of both procoagulant and plasminogen activator 
activities are augmented in vin-0 by activated lymphocytes or their products (32-35). Similarly, 
stimulation of both monocyte plasminogen activator and procoagulant activity has been shown to 
be in vin0 correlates of cell mediated immunity in vivo (34,35). The competing interplay between 
procoagulant and fibrinolytic activity may regulate local accumulation of fibrin matrix. These íïlnin 
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matrices potentiaIly contribute to many aspects of infhunmatory responses, as fibrinogenderived 
products are chemotactic for leukocytes, inhibit lymphocyte function, affect macrophage mobility, 
and provide a favorable substrate for ingrowth of fibroblasts (35-39). We therefore sought to 
expand on earlier observations (17,20,21) by examining the effects of arachidonic acid metabolites 
on concurrent expression of tissue thromboplastin and plasminogen activator activities by rabbit 
alveolar macrophages. 
We found that indomethacin suppressed augmentation of PC activity of LCM and PMA-treated 
macrophages, while stimulating both released and cell-associated plasminogen activator activity 
(Figures 1 and 3). These effects of indomethacin could only be reversed by addition of exogenous 
PGE and not by any other cyclooxygenase metabolite tested @gure 2). This indicates that 
indomethacin affects macrophage PC and PA activities by blocking endogenous production of 
PGE2. Exogenous PGE2 enhanced PC suppression beyond the leve1 of maximal stimulation by 
LCM alone, while the same concentrations markedly suppressed PA activity. PGE2 had a 
qualitatively similar but smaller effect on the markedly elevated PC and PA activities of PMA- 
stimulated macrophages. It is notable that PGE2 only augmented PC activity of cells that were 
conditioned by a second stimulus, but suppressed PA production by both normal and conditioned 
macrophages. Thus, PG& may have differential effects on these two activities depending on the 
degree to which macrophages are co-stimulated with inflammatory mediators. 
Most of the effects of PGE2 on leukocyte functions are presently believed to occur by 
stimulating adenylate cyclase activity (28,29). This prompted US to consider whether intracellular 
cAMP levels ultimately regulate expression of PC and PA activities. Treating normal or PMA- 
conditioned macrophages with dibutyryl cAMP caused only a variable and statistically insignificant 
increase in PC activity, but suppression of PA was comparable to the maximal effect of PGEp 
@gure 4). However, it is clear that augmentation of intracellular cyclic AMP is not a sufficient 
explanation for the effects of PGE2, as we have found that stimulating these cells with adenosine 
analogues under identical culture conditions causes a similar increase in inuacellular cyclic AMP, 
but opposite directional changes in both PC and PA activites (40). Thus, it appears that 
modulation of adenylate cyclase activity is either compartmentalized to agonist-specific sites, or 
altematively, PGEp may affect cellular functions by mechanisms unrelated to cyclic AMP. 
The modulation by PGE2 of both tissue thromboplastin and plasminogen activator activities is 
certainly consistent with a growing body of evidente that mononuclear phagocytes exert feedback 
inhibition on many effector functions through endogenous secretion of PGE2. This arachidonic 
acid metabolite is known to have suppressive effects in vitro on macrophage proliferation, 
production of complement proteins and oxygen metabolites (l-6), and more recently, expression of 
histocompatibility antigens, and release of interleukin-1 and tumor necrosis factor (7-9). In 
contrast, PGE2 enhances expression of FC receptors and collagenase production while 
phagocytosis and tumor killing are variably affected (10-15). Some of these effects may be 
responsible for the modulation of cell mediated immune reactions by arachidonic acid metabolites 
in vivo (16). 
To summarize, we have shown that PGE2 has opposite modulating effects in vitro on 
expression by rabbit alveolar macrophages of tissue thromboplastin and plasminogen activator 
activities. These combined effects may interact to promote fibrin accumulation at inflammatory 
foei. If this is so, this would establish PGE2 as an important mediator interrelating the processes 
of inflammation and coagulation/fibrinolysis. These results further suggest that cyclooxygenase 
inhibitors and exogenous PGE2 may be useful in future studies to investigate the role of tïbrin 
matrix deposition in the pathogenesis of inflammation and tissue repair. Finally, it is clear that the 
potential influences of contaminating or endogenously produced PGE2 must be considered in 
future studies of macrophage procoagulant and plasminogen activator activities. 
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